Skip to main content
NRXP
NASDAQ Life Sciences

NRx Pharma的无防腐剂氯胺酮即将获得FDA批准，仅有轻微的标签反馈

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$2.23
Mkt Cap
$72.749M
52W Low
$1.58
52W High
$3.84
Market data snapshot near publication time

summarizeSummary

NRx Pharmaceuticals宣布了一项重大监管里程碑，即从FDA的仿制药办公室收到了关于其无防腐剂氯胺酮申请的积极反馈。FDA的评论仅限于拟议标签的轻微格式更改，表明前进道路平坦。该公司预计将在本月提交最终标签，预计在2026年夏天获得全面ANDA批准。这一发展对于NRx来说至关重要，尤其是考虑到其最近的10-K提交，其中包括“持续经营”警告和大量股权稀释。FDA已将氯胺酮确定为“高度战略产品”，因为美国供应短缺，NRx的美国制造产品可能会显著解决这一需求，可能提供大量收入。交易者应监控最终标签提交和预计2026年夏天的批准，以及与静脉注射氯胺酮相关的NDA的进展。

在该公告发布时，NRXP的交易价格为$2.23，交易所为NASDAQ，所属行业为Life Sciences，市值约为$7274.9万。 52周交易区间为$1.58至$3.84。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed NRXP - Latest Insights

NRXP
Apr 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
FDA Gives Positive Feedback on NRx Pharma's Preservative-Free Ketamine, Targets Summer 2026 Approval
Sentiment: Positive
View Wiseek Article
NRXP
Apr 20, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Presidential Order to Fast-Track Psychedelic Drug Approvals Directly Benefits NRx Pharmaceuticals
Sentiment: Positive
View Wiseek Article
NRXP
Apr 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
NRx Pharma's Preservative-Free Ketamine Nears FDA Approval with Minor Labeling Feedback
Sentiment: Positive
View Wiseek Article
NRXP
Mar 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Hope Therapeutics, NRXP Subsidiary, Partners with Emobot to Deploy AI-Powered Depression Monitoring
Sentiment: Positive
View Wiseek Article
NRXP
Mar 24, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
7
Stockholders Approve Significant Increase in Annual Incentive Plan Share Reserve
Sentiment: Negative
View Wiseek Article
NRXP
Mar 23, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
8
NRX Pharmaceuticals Reports Going Concern, Massive Dilution, and Key Regulatory Progress in Annual 10-K
Sentiment: Negative
View Wiseek Article
NRXP
Mar 16, 2026, 7:36 AM EDT
Source: Reuters
Importance Score:
9
FDA Confirms Clear, Accelerated NDA Path for NRX-100 by June 2026, No New Trials Required
Sentiment: Positive
View Wiseek Article
NRXP
Feb 23, 2026, 5:00 PM EST
Filing Type: DEF 14A
Importance Score:
8
NRX Pharmaceuticals Seeks Shareholder Approval for Substantial Increase in Equity Incentive Plan Share Reserve
Sentiment: Negative
View Wiseek Article
NRXP
Feb 17, 2026, 9:21 AM EST
Filing Type: 8-K
Importance Score:
9
NRX Pharmaceuticals Secures Clear FDA Path for Full NDA Approval of NRX-100 with Broader Indication
Sentiment: Positive
View Wiseek Article
NRXP
Feb 17, 2026, 9:20 AM EST
Filing Type: 424B5
Importance Score:
9
NRX Pharmaceuticals Announces Highly Dilutive $20M At-The-Market Equity Offering
Sentiment: Negative
View Wiseek Article